You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Efficacy of methyprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson’s disease
  1. C E Clarke1
  1. 1Department of Neurology, City Hospital, Dudley Road, Birmingham B18 7QH, UK; c.e.clarke@bham.ac.uk

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      I was astonished to find that Sato and colleagues were able to identify 40 cases of neuroleptic malignant syndrome (NMS) in patients with Parkinson’s disease from a single institution over three years.1 At a recent neurosciences grand round in Birmingham, UK, which has an interest in Parkinson’s disease research, we could only recall two such cases in living memory.

      There are two possible explanations for this high incidence of NMS. Firstly, in Japan the Parkinson’s disease population may be more prone to developing NMS when their anti-parkinsonian medication is reduced. This could be due to genotypic differences between Japanese and Western populations. …

      View Full Text